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Abstract
Fractures in horses–whether simple fractures with just one clean break, or incomplete
greenstick with stress fractures, or complications such as shattered bones can all be either
minimal or even catastrophic. Thus, improvement in fracture healing is a hallmark in equine
orthopedics. The fracture healing process implements a complex sequence of events
including the initial inflammatory phase removing damaged tissue, re-establishment of ves-
sels and mesenchymal stromal cells, a soft and hard callus phase closing the fracture gap
as well as the remodeling phase shaping the bone to a scar-free tissue. Detailed knowledge
on processes in equine fracture healing in general and on the initial phase in particular is
apparently very limited. Therefore, we generated equine in vitro fracture hematoma models
(FH models) to study time-dependent changes in cell composition and RNA-expression for
the most prominent cells in the FH model (immune cells, mesenchymal stromal cells) under
conditions most closely adapted to the in vivo situation (hypoxia) by using flow cytometry
and qPCR. In order to analyze the impact of mesenchymal stromal cells in greater detail, we
also incubated blood clots without the addition of mesenchymal stromal cells under the
same conditions as a control. We observed a superior survival capacity of mesenchymal
stromal cells over immune cells within our FH model maintained under hypoxia. Further-
more, we demonstrate an upregulation of relevant angiogenic, osteogenic and hypoxia-
induced markers within 48 h, a time well-known to be crucial for proper fracture healing.
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Introduction
Fractures in horses are often fatal, extremely expensive to treat, and in certain cases an injury
leading to euthanasia [1, 2]. Additionally, equine fractures and their subsequent treatment are
of great economic interest [3], especially for horses deployed in racing. Various studies indi-
cated an incidence of fractures in races between 1–2% per race start [2, 4, 5], with pelvic and
tibial stress fractures identified as the most common cases of fracture [5]. Furthermore, the
number of horses used in leisure sports is still increasing and includes a trend towards free-
range husbandries in groups leading potentially to injuries and contortions especially in the
fetlock area [6, 7]. Similar to treatment in humans, current strategies towards long bone frac-
tures in horses focus on stabilization of the fracture site by means of screws or nails [8, 9].
Nowadays more elicit methods of treatment utilizing internal fixators [1], locking compression
plates [10], external fixators [11] or hydrogels [12] are being applied in clinics. Moreover, cell
therapy with either mesenchymal stromal cells [13, 14] or osteoprogenitor cells [15] is of
upcoming interest especially for fractures that cannot be stabilized due to the location (fetlock,
coffin bone). Nevertheless, the biggest challenge still remains the appropriate stabilization that
remains perpetuated during the recovery time after surgery when approximately 400–600 kg
of body weight are loaded onto the bones. As to the processes of fracture healing and particu-
larly those during the initial phase of fracture healing, only little is known. In horses, bone
healing is generally considered to be delayed [16] and contradictory to phylogenetically lower
developed animals, the bone quality is diminished after trauma [17].
Generally, fracture healing can be divided into four different phases: (i) initial/inflamma-
tory phase, (ii) soft callus formation, (iii) hard callus formation, and (iv) remodelling phase.
During fracture, the bone marrow channel is shattered and evading cells such as mesenchymal
stromal cells (MSCs), hematopoietic stem cells (HSC), immune cells and their precursor cells
are mixed with cells from ruptured blood vessels (immune cells) within the fracture gap. These
cells coagulate and form the so-called fracture hematoma (FH), which initiates the ongoing
inflammatory phase within a hypoxic milieu [18]. Main research progress focusing on the ini-
tial phase has been conducted in sheep or rodents [19, 20], facing the problem of translation
towards the human situation and/or the horse as a patient. Mice for instance lack the Haver-
sian canal system [21], which is typical for human and equine bone physiology and remain in
general an arguable model for disease patterns with ongoing inflammation processes [22]. In
contrast, large animal models show considerably more similarity to human bone physiology
concomitant processes when it comes to the pathophysiology of fracture healing [23]. In a
human ex vivo study in 2011, Hoff et al. could show that besides myeloid cells of the innate
immune system (monocytes, granulocytes) and cells of the adaptive immune system (T and B
cells), also hematopoietic stem cells and MSCs are prominent cells in the FH [18].
Based on the general assumption that within the initial phase of bone healing immediately
following the trauma, a hematoma is generated which accumulates cells from both peripheral
and intramedullary blood, as well as bone marrow cells including mesenchymal stromal cells
(MSCs) [24]. The initial phase is known to involve an acute inflammatory response including
the production and the release of several important molecules, such as IL6, IL8 and MIF [25],
and the recruitment of MSCs in order to generate a primary cartilaginous callus [24]. Thus, we
generated a blood clot with MSCs to simulate the shift from the initial hematoma to the soft
callus phase and to determine the importance of MSCs in the equine fracture healing process.
In brief, the rationale of our study was to study the influence of MSCs, which are considered to
be the main driver of tissue regeneration during the initial phase of fracture healing, since
MSCs are the progenitor cells both for cartilage (endochondral ossification) and bone cells
(intramembranous ossification). We also implemented microenvironmental conditions found
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at the fracture site in vivo (hypoxia). For simulating the hypoxic conditions, we incubated our
FH models under hypoxia (1% O2), with normoxia serving as a control. To underline the
impact of MSCs, we also incubated in parallel blood clots without the supplementation of
MSCs as a second control. This way we had the opportunity to (i) contextualize our data to
existing in vivo and ex vivo data and (ii) to use this system to eventually analyze the impact of
fracture healing-relevant drugs or therapies in subsequent studies. To this end, we used our in
vitro FH model in order to study the influence of hypoxia and mesenchymal stromal cells on
the initial phase of fracture healing.
Materials and methods
Blood samples
EDTA blood samples (residual material from diagnostic blood drawings) were obtained from
the equine clinic at the Department of Veterinary Medicine, Freie Universita¨t Berlin (clinic’s
own horses). The horses showed no indication of illness, systemic inflammation or infection.
For the in vitro FH models we used the blood of three different horses and mixed them with
2.2 x 105 MSCs. Correspondingly, we used the blood of three different horses for the coagula-
tion of the blood clots. Age and gender of the respective donors can be found in Table B in S1
Appendix. Blood collection was approved by the local legal representative animal rights pro-
tection authorities (Landesamt fu¨r Gesundheit und Soziales Berlin: O 344/13)
Bone marrow-derived MSC isolation and incubation
Bone marrow was obtained from the sternum shortly after euthanasia from horses which were
euthanatized for other ethical justifiable reasons (cadavers) at the equine clinic Seeburg (Dall-
gow-Do¨beritz, Germany). Horses showed no indices of illness, systemic inflammation or
infection. Bone marrow was transported aseptically in phosphate-buffered saline (PBS) and at
RT. Collected bone marrow was transferred into 175 cm2 cell culture flasks (Greiner Bio-one,
Kremsmu¨nster, Austria) and flushed with 25 ml of DMEM plus GlutaMAX (Thermo Fisher
Scientific, Waltham, USA) supplemented with 20% (v/v) StemMACS MSC Expansion Media
Kit XF (Miltenyi Biotech, Bergisch Gladbach, Germany), 10% (v/v) FCS (Thermo Fisher, Wal-
tham, USA), 100 units/ml penicillin and 100 mg/ml streptomycin (Thermo Fisher, Waltham,
USA), further referred to here as MSC culture medium. Incubation was carried out at 37˚ C in
humidified atmosphere containing 5% CO2. The MSC culture medium was completely
replaced after two days of incubation in order to remove remaining bone marrow, blood and
non-adherent cells. Hereafter the medium was replaced weekly.
Differentiation and characterization of bone marrow-derived MSCs
To ascertain the differentiation capability, cells were plated at 1x104 cells/well in 96-well plates
(Greiner Bio-one, Kremsmu¨nster, Austria) and incubated in the appropriate differentiation
medium for 3 weeks.
Osteogenesis: MSCs were differentiated in StemMACS OsteoDiff (Miltenyi Biotech, Ber-
gisch Gladbach, Germany). Cells were fixated with a 4% (w/v) paraformaldehyde solution
(Carl Roth, Karlsruhe, Germany) for 10 min at RT and stained with 2% (w/v) Alizarin Red (in
H2Odd, pH 4.1; Sigma Aldrich, St. Louis, USA) for 10 min at RT.
Adipogenesis: MSCs were incubated in α-MEM (Sigma Aldrich, St. Louis, USA) supple-
mented with 10% (v/v) human serum AB (EUROCLONE, Via Figino, Italian), 100 units/ml
penicillin, 100 mg/ml streptomycin, 12 mM L-glutamine (GE Healthcare, Little Chalfont,
England), 5 μg/ml insulin (Lilly, Bad Homburg, Germany), 50 μM indomethacin (Sigma
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Aldrich), 1 μM dexamethasone (Sigma Aldrich) and 0.5 μM isobutylmethylxanthine (Sigma
Aldrich, St. Louis, USA). Cells were fixed with 4% (w/v) paraformaldehyde for 10 min at RT
and stained with 0.3% (v/v) Oil Red O (Sigma Aldrich, St. Louis, USA) in 60% (v/v) isopropa-
nol (Merck, Darmstadt, Germany) for 15 min.
Further phenotypic characterization was carried out by the expression analysis of three sur-
face MSC markers. Antibodies against equine CD29 and CD105 were used as positive markers
and an antibody against equine CD14 as negative marker. Further procedure is described
below (“Flow cytometric analysis”).
Establishment of 3D fracture hematoma model and control hematomas
For the production of one hematoma model, 100 μl of blood (collected in vacutainer tubes
with EDTA) were mixed with 2.2 x 105 MSCs and 100 μl of a 10 mM CaCl2 solution in a
96-well-plate (round bottom, Greiner Bio-one, Kremsmu¨nster, Austria). Control hematomas
(blood clots) were produced analogously without any supply of MSCs. After 30 min incubation
at 37˚C the blood clots (n = 4) and the FH models (n = 4) were transferred into DMEM + Glu-
taMAX supplemented with 10% (v/v) FCS, 100 units/ml penicillin, 100 mg/ml streptomycin,
0.2% (w/v) β-glycerophosphate (Sigma Aldrich, St. Louis, USA), 10 nM dexamethasone
(Sigma Aldrich, St. Louis, USA) and 0.002% (w/v) l-ascorbic acid (Sigma Aldrich, St. Louis,
USA), further referred as osteogenic differentiation medium. Hematomas/blood clots were
incubated for 6, 12, 24, 48, and 72 h under hypoxia at 5% CO2 and 1% O2, balanced with N2.
Normoxic controls were incubated at 37˚C under 5% CO2 balanced with room-air in a humid-
ified atmosphere (resulting in 18% O2) for 6, 12, 24, 48, and 72 h as well.
RNA isolation
After incubation, coagulated hematoma models were washed with PBS and cells were sepa-
rated via a cell strainer (70 μm, Corning, New York, USA). Erythrocyte lysis was performed
(erythrocyte lysis buffer: 0.01 M KHCO3, 0.155 M NH4Cl, 0.1 mM EDTA, pH 7.5) for 6 min at
4˚C three times, and cells were washed with 0.5% (w/v) BSA in PBS (PBS/BSA). Total RNA
was extracted using Arcturus PicoPure RNA Isolation Kit (Applied Biosystems, Foster City,
USA), according to the manufacturer´s instructions and the RNA concentration was deter-
mined using Nanodrop ND-1000 (Peqlab Biotechnologie, Erlangen, Germany). RNA was
stored at -80˚C until further processing.
Quantitative PCR (qPCR)
The cDNA was synthesized by reverse transcription using TaqMan Reverse Transcription
Reagents (Applied Biosystems) for RNA concentrations >10 ng/μl or Sensiscript Reverse
Transcription Kit (QIAGEN GmbH, Hilden, Germany) for RNA concentrations� 10 ng/μl.
cDNA was stored at -20˚C until further processing. qPCR was performed using the DyNAmo
Flash SYBR Green qPCR Kit (Thermo Fisher, Waltham, USA) and the Stratagene Mx3000P
(Agilent Technologies, California, USA). Initial denaturation was for 7 min at 98˚C followed
by 45 cycles with 5 s at 98˚C, 7 s at 58˚C and 9 s at 72˚C. Finally, the melting curve was ana-
lyzed by a stepwise increase of the temperature from 50 to 98˚C every 30 s.
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Data were normalized to the expression of Beta-2-Microglobulin (B2M) and to the time
point 0 h, using the ΔΔCt-method. Focusing on the influence of hypoxia and the effect of
MSCs on a model of a fracture hematoma using equine samples under a sterile inflammatory
situation, we had to exclude commonly used housekeeping genes that are known to be regu-
lated by hypoxia or inflammation such as GAPDH or ACTB. We have ultimately chosen B2M
as a housekeeping gene which has been reported to be a stable housekeeping gene in horse and
under hypoxic conditions at least in human MSCs [26, 27]. Furthermore, using qPCR based
on the same template concentrations we observed neglectable deviations of the Ct-values of
B2M with regard to incubation duration for different time points (0 h, 12 h, 48 h) data not
shown.
Flow cytometric analysis
After erythrocyte lysis, the isolated cells were washed with PBS/BSA. After Fc-receptor block-
ing with Flebogamma the cells were washed with PBS/BSA and antibody staining was per-
formed for 15 min on ice. Table A in S1 Appendix shows all antibodies with their specificity,
dilution used and the corresponding isotype controls. All isotype controls were obtained from
Miltenyi Biotech GmbH (Bergisch Gladbach, Germany). The cells were washed with PBS/BSA
and incubated with 1:25-diluted 7-AAD (BioLegend, San Diego, USA) for 15 min at RT. After
a further washing step with PBS/BSA, the cells were resuspended in 0.05% (w/v) NaN3 in PBS/
BSA (PBS/BSA/Azide). The cells were recorded using flow cytometry with a MACS Quant
Analyzer (Miltenyi Biotech, Bergisch Gladbach, Germany) and analyzed with FlowJo software
(Tree Star, USA). The antibodies and gating strategy utilized are given in the supplementary
files (Table A and Fig A in S1 Appendix).
Embedding, cryosections and DAPI stain
For immunofluorescence, FH models (0 h, 24 h and 48 h) were embedded as follows: FH mod-
els were transferred into 4% paraformaldehyde, then into a 10%, 20% and finally 30% glucose
solution, each for 24 h. Storage was at 4˚C. Cryo-embedding was followed by cryosections as
described previously [28]. Slides were air dried and subsequently stained with DAPI. The
DAPI staining solution was 0.1% (v/v) DAPI (Sigma Aldrich, St. Louis, USA); 0.1% (v/v)
Tween 20 (Carl Roth, Karlsruhe, Germany); 5% (v/v) FCS (Thermo Fisher, Waltham, USA) in
PBS. The whole procedure was performed at RT. Sections were first incubated in PBS with
0.1% (v/v) Tween 20 for 10 min. After 10 min incubation in DAPI staining solution, the sec-
tions were washed three times in PBS with 0.1% (v/v) Tween 20. Stained sections were put on
a slide and then mounted (Fluoromount™ Aqueous Mounting Medium, Sigma Aldrich,
St. Louis, USA) under a cover slip. Examination of the sections was performed and photos
were taken, using a KEYENCE BZ-X700 fluorescence microscope and depicted in pseudo-
colors.
Statistical analysis
Statistical tests were performed using Graph Pad Prism Software (La Jolla, USA). Differences
were compared using the Mann–Whitney U-test. Probability values of p<0.05 were
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considered to be statistically significant, and values of p<0.1 were considered to have a statisti-
cal trend (�p<0.05; +p<0.1).
Results
MSCs play a fundamental role in the initial phase of fracture healing. Therefore, MSCs repre-
sent an important cell fraction within our hematoma models. For the use of MSCs, we estab-
lished well-defined minimal criteria based on their potential to adhere to plastics, to
differentiate into osteoblasts and adipocytes, and to express typical surface markers. Only
MSCs that fulfill these criteria were utilized to establish the equine in vitro FH model, consist-
ing of peripheral blood and MSCs.After cultivation for three passages, the MSCs adhered to
the plastic surface and showed their typical fibroblastoid morphology (Fig 1A). They also
could be differentiated into the osteogenic lineage as the Alizarin Red S staining showed
Fig 1. Bone marrow-derived cells obtained from sternum-biopsies are characterized as MSCs. Characterization of equine bone marrow-derived MSCs obtained
from sternum-biopsies with regard to their potential to (A) adhere to plastic surfaces and typical morphology, their differentiation potential towards adipogenic and
osteogenic lineage and (B) express surface markers CD29, CD105, and CD14 (unstained fractions, isotype control stainings and antigen-specific stainings are depicted
in light grey, dark grey and black, respectively).
https://doi.org/10.1371/journal.pone.0214276.g001
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calcium-complexes stained in red colour and the adipogenic lineage as the cells secrete lipid
droplets which are stained red via Red oil staining (Fig 1B). Additionally, the typical surface
markers CD29 and CD105 were expressed with no expression of the exclusion marker CD14
(Fig 1C; Table A in S1 Appendix).
Cell composition of in vitro FH models under normoxic conditions
To mimic the initial phase of fracture healing in vitro, we generated in vitro FH models by mix-
ing and coagulating MSCs and blood cells. After incubation of the in vitro FH models for 6, 12,
24, 48, and 72 h under normoxic conditions (37˚C, 5% CO2, 18% O2), we observed a continu-
ous decline in the frequency of cells alive which resulted in 45 ± 3% of cells alive after an incu-
bation period of 72 h (Fig 2A). Within the FH model, the frequency of immune cells decreased
over time, while the frequency of MSCs increased within the first 12 h. As a result, the MSC
population became the major cell population in the in vitro FH model, although it decreased
between 12 and 72 h (Fig 2A). With regard to the proportion of immune cells, we observed a
continuous decrease in the frequency of granulocytes over time. The frequency of monocytes
was negligible, with almost no cells detectable after 6 h of cultivation, while the frequency of
CD8+ cells also decreased perpetually. Interestingly, the most prominent population at 0 h–
namely CD4+ T cells–remains the most stable cell population within the incubation period
analyzed (Fig 2A). In contrast, with regard to the blood clots (Fig B in S1 Appendix) the fre-
quency of granulocytes as well as T cells was very stable. As to the spatial distribution, we
observed no clustering of cells but an even distribution within the FH model using DAPI-
staining (Fig 2B).
Fig 2. Immune cell vitality in the FH model decreases over time irrespective of subpopulation and spatial
distribution after incubation under normoxic conditions. (A) Frequency of immune cell populations (granulocytes,
CD14+ monocytes, CD4+ T cells, CD8+ T cells) and MSCs (CD29+, CD 105+, CD14-) negative for 7-AAD present in
the in vitro FH model as incubated in osteogenic differentiation medium under normoxic conditions (37˚C, 5% CO2,
18% O2) for 6, 12, 24, 48, and 72 h (mean ± SEM, n = 3). Depicted is the frequency of total cells and the corresponding
frequencies of the cell populations. (B) Spatial distribution of cells within the in vitro FH model as determined by
DAPI-staining and depicted as representative staining for incubation periods of 0, 24, and 48 h (The dotted line
indicates the border of the in vitro hematoma; FH = area of the fracture hematoma model and OA = outer area).
https://doi.org/10.1371/journal.pone.0214276.g002
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Cell composition of in vitro FH models under hypoxic conditions
To mimic the restricted microenvironment in the initial phase of fracture healing more ade-
quately, we generated in vitro FH models and incubated them under hypoxic conditions
(37˚C, 5% CO2, 1% O2) for 6, 12, 24, 48, and 72 h. We observed a perpetual decline of the cells
alive with a final frequency of 43 ± 2% after 72 h of incubation (Fig 3A). With regard to the
immune cell populations, the frequency of CD4+ T cells and CD8+ T cells again constantly
decreased over time, whereas the frequency of granulocytes increased from zero to 12 h before
massively decreasing. The frequency of monocytes alive was barely detectable at any time
point analyzed. Finally, none of the analyzed immune cell populations survived the FH model
after 72 h of cultivation under hypoxic conditions. In contrast, the proportion of MSCs within
the FH model permanently increased from a ratio of 20% ± 1% at 0 h to 42 ± 2% at 72 h after
cultivation (Fig 3A). With regard to the blood clots (Fig B in S1 Appendix), we observed a sta-
ble frequency of granulocytes and T cells. Regarding the spatial distribution, we again observed
no clustering of cells but an even distribution within the FH model using DAPI-staining (Fig
3B).
Impact of oxygen availability on cellular vitality and composition in the in
vitro FH models
When comparing cellular vitality and composition of the FH models incubated under nor-
moxia with those incubated under hypoxia, we observed no differences in respect to overall
cell survival, either after 72 h, or throughout the whole decline in time. However, as far as the
cellular composition is concerned, the frequencies of all immune cell populations in the FH
model declined under hypoxia, whereas under normoxia, survival of CD4+ and CD8+ T cells
Fig 3. Hypoxia favors survival of MSCs while decreasing immune cell fractions. (A) Frequency of immune cell
populations (granulocytes, CD14+ monocytes, CD4+ T cells, CD8+ T cells) and MSCs (CD29+, CD 105+, CD14-)
negative for 7-AAD in the FH models cultured in osteogenic differentiation medium under hypoxic conditions (37˚C,
5% CO2, 1% O2) for 6, 12, 24, 48, and 72 h (mean ± SEM, n = 3). Depicted is the frequency of total cells and the
corresponding frequencies of the cell populations. (B) Spatial distribution of cells within the FH model as determined
by DAPI-staining and depicted as representative staining for 0, 24, and 48 h of incubation (The dotted line indicates
the border of the in vitro hematoma; FH = area of the fracture hematoma model and OA = outer area).
https://doi.org/10.1371/journal.pone.0214276.g003
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after 72 h of incubation was significantly higher than that under hypoxic incubation (Fig 4). In
contrast, the frequency of granulocytes remains unaffected by the incubation conditions, and
for monocytes the case was likewise negligible. Hence, the frequency of MSCs was significantly
higher under hypoxic conditions after 72 h of cultivation when compared to that of the corre-
sponding control (Fig 4).
MSCs along with their time-dependent increase were by far the most abundant cells, a most
striking situation seen from 12 to 72 h. Compared to normoxic conditions, MSCs survived bet-
ter under hypoxic conditions, whereas immune cells seem to have a diminished survival rate
(Fig 4).
Time-dependent RNA-expression of fracture-healing-relevant markers in
the in vitro FH models
To analyze the impact of hypoxia on all cells in the FH model, we focused on markers for oste-
ogenesis, glycolytic adaptation towards hypoxia and angiogenesis on the transcriptional level
(Fig 5). Therefore we analyzed the RNA-expression of fracture-relevant markers. We culti-
vated the in vitro hematomas for 6, 12 and 48 h. Within the hematomas, osteogenic (RUNX2,
SPP1), angiogenic (VEGFA, MIF) as well as hypoxia-induced (LDHA, PGK1, PFKFB3,
Fig 4. Hypoxia favors survival of MSCs while decreasing granulocytes, CD4+ and CD8+ immune cells. Frequency of granulocytes, CD4+ and CD8
+ immune cells negative for 7-AAD in the FH model cultured in osteogenic differentiation medium under either normoxic (grey) or hypoxic (black)
conditions (n = 3). Statistical analysis was conducted using the Mann-Whitney U-test, �p<0.05.
https://doi.org/10.1371/journal.pone.0214276.g004
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SLC2A1) markers were higher expressed after 48 h. Concerning the osteogenic markers,
we demonstrated a time-dependent upregulation of RUNX2 and SPP1. While RUNX2 was
upregulated after 12 h of cultivation, the highest upregulation of SPP1 was observed at 48 h.
Additionally, this effect was even stronger under hypoxic conditions, where RUNX2 was upre-
gulated to a higher extent. In contrast, the adipogenic transcription factor PPARG was less
Fig 5. Within the FH models, osteogenic, hypoxia-induced and angiogenic markers were upregulated over time until 48 h of incubation.
Depicted is the relative RNA-expression of the osteogenic markers RUNX2, SPP1, the adipogenic marker PPARG, the hypoxia induced genes
LDHA, PGK1, PFKFB3, SLC2A1, and the angiogenic genes VEGFA, and MIF within the in vitro FH models after cultivation in osteogenic
differentiation medium for 6, 12, and 48 h under either normoxia (white bars) or hypoxia (black bars). All values are normalized to the
“housekeeping gene” B2M and 0 h (Mean ± SEM, n = 3). Statistical analysis was conducted using Mann-Whitney U-test.
https://doi.org/10.1371/journal.pone.0214276.g005
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strongly induced in FH models incubated under hypoxic conditions. Drawing the focus towards
angiogenic markers, we could show the upregulation of typical markers (peaks: VEGFA after 12
and MIF after 48 h). Interestingly, both VEGFA and MIF showed higher levels of expression in
FH models incubated under hypoxic conditions. LDHA, PGK1, PFKFB3 and SLC2A1 were also
upregulated at least after 12 h. After 48 h, the majority of genes analyzed were expressed to a
higher extent under hypoxic conditions except for PFKFB3 and PPARG (Fig 5).
Differences of the mRNA-expression of in vitro hematomas versus blood
coagulates after 48 h of cultivation under normoxic or hypoxic conditions
To analyze if the observed changes in gene expression patterns are due to the different survival
rates of the analyzed immune cell populations and MSCs, we compared the data gained from
in vitro hematomas to blood coagulates without MSCs. Focusing on the differences between
the mRNA-expression of blood coagulates and in vitro hematomas, we could show that except
for SPP1 the expression of relevant genes was higher in the in vitro hematomas (significant for
PFKFB3 and VEGFA). In the in vitro FH model, osteogenic-relevant genes (RUNX2, SPP1)
were upregulated, even more pronounced under hypoxic conditions, whereas the adipogenic
marker PPARG was upregulated, but about 100 times less under hypoxic conditions. Hypoxia-
induced genes (PGK1, PFKFB3 and SLC2A1) were also upregulated under both cultivation
methods, except for SLC2A1 which was only upregulated under hypoxic conditions. PGK1
and SLC2A1 showed a higher expression under hypoxic conditions. For the angiogenic mark-
ers VEGFA and MIF as well as for the pH-regulating marker LDHA, we could show an upregu-
lated expression which was even more evident under the influence of hypoxia (Fig 6).
Discussion
To study the underlying cellular mechanisms of the initial inflammatory phase of fracture heal-
ing in horses, we aimed to establish an equine in vitro FH model. To this end, we first created
protocols for the isolation and characterization of major cell types involved in the generation
of the FH model, namely immune cells–released from the ruptured vessels and from the bone
marrow–and mesenchymal stromal cells (MSCs) from bone and bone marrow. The limited
availability of suitable antibodies for immunological characterization but also the limited
knowledge of lineage markers for equine cells especially for equine MSCs belong to the chal-
lenging issues we wanted to address in the study presented here.
To characterize MSCs, standardized criteria for human material have already been estab-
lished and defined more than ten years ago [29]. In brief, human MSCs have to fulfill minimal
requirements including attachment to plastic surfaces, the capacity to differentiate into multi-
ple lineage [30], as verified by differentiation towards osteogenic, chondrogenic and adipo-
genic lineage, and finally the presence or absence of typical surface markers (CD73+, CD90+,
CD105+; CD45-, CD34-, CD14-, CD19- and HLA-DR-) [29]. Focusing on equine MSCs, it is
disparately more difficult to characterize these cells in a similar way. Although a variety of
characterization procedures have already been described [31–34], only few surface markers are
available for immunophenotyping due to the limited availability of suitable antibodies. Here,
we characterized MSCs by demonstrating (i) plastic adherence, (ii) differentiation towards
osteogenic (demonstrated by Alizarin Red staining) and adipogenic (demonstrated by Red Oil
staining) lineage, and (iii) immunological characterization using CD105 and CD29, previously
described as stable equine MSCs markers and widely used to characterize equine MSCs [35–
38] and CD14 as a negative marker (Fig A and Table A in S1 Appendix). These have also been
previously demonstrated to characterize equine monocytes (2013) [39]. We defined this char-
acterization procedure as a minimum criterion for the use of equine MSCs within our study.
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For the characterization of equine immune cells, we used antibodies against CD4, CD8, and
CD14, while granulocytes were determined by granularity and size using flow cytometry
(Table A in Appendix 1). Separation of MSCs from the immune cell populations in the FH
model was achieved by flow cytometry (Fig A in S1 Appendix).
Fig 6. Osteogenic, hypoxia-induced and angiogenic markers were upregulated in the in vitro FH models compared to blood coagulates.
Depicted is the relative RNA-expression of the osteogenic markers RUNX2, SPP1, the adipogenic marker PPARG, the hypoxia induced genes LDHA,
PGK1, PFKFB3, SLC2A1 and the angiogenic genes VEGFA and MIF within the FH models and the blood-only coagulates after cultivation in
osteogenic differentiation medium for 48 h under either normoxic (white bars) or hypoxic conditions (black bars). All values are normalized to the
“housekeeping gene” B2M and to 0 h (mean ± SEM, blood clots: n = 4, FH models: n = 3). Statistical analysis was conducted using Mann-Whitney
U-test, �p<0.05.
https://doi.org/10.1371/journal.pone.0214276.g006
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Although in vitro FH models were generated in a standardized manner with regard to cell
numbers and incubation times, we had to face limitations in terms of low cell recovery from
coagulates after incubation, variations in hematoma size after coagulation and a massive
impact on cell survival after incubation (Figs 2 and 3).
Analyzing the impact of a restricted microenvironment by focusing on hypoxia in our in
vitro model, we did not observe any difference between normoxia and hypoxia concerning
overall cell survival (Figs 2 and 3). However, we did observe a shift in the distribution of cell
population towards an increase in the proportion of MSCs after incubation under hypoxic
conditions (Fig 3). We assume that MSCs, well-known key players in the process of fracture
healing [40–42], may promote the termination of the inflammatory phase especially in a hyp-
oxic microenvironment, and this may resemble the in vivo situation at the fracture site [18].
Thus, MSCs can be assumed to be likely suitable candidates in cell-based therapeutic strategies
to overcome fracture healing disorders in horses and humans [13, 14]. Additionally, we had
observed previously that the osteogenic differentiation of human MSCs is enhanced in a hyp-
oxic microenvironment but also that it does not influence cell survival or proliferation [43].
Conversely, Ranera et al. (2012) demonstrated that hypoxia limits the proliferation of equine
MSCs in 2D cultures [34]. Whether or not these differences are species-specific needs to be
clarified.
Focusing on myeloid cells such as monocytes and polymorph nuclear cells (PMNC), we
observed a time-dependent decline of their frequencies within the in vitro FH model without
any significant impact of hypoxia on cell survival (Figs 2–4). In general, the role of neutrophils
with regard to fracture healing has to our knowledge been poorly investigated or is discussed
controversially, although granulocytes are the most abundant cells in the early FH [44]. Groo-
gard et al. (1990) reported that neutropenia in mice did not have any significant effect on frac-
ture healing [45]. In addition, Chung et al. (2006) observed a slight increase of bony trabeculae
when treating young rats with neutrophil-neutralizing antiserum in a growth plate injury
model [46]. In the human in vitro FH model, which was performed recently from our group
neutrophils seem to only marginally influence fracture healing, while being time-dependently
depleted in the FH model, and even more strongly so under hypoxic conditions [47]. In con-
trast, a study of Kovtun et al. (2016) reveals a crucial role of neutrophils in bone healing [44].
They drastically reduced the number of neutrophils using a Ly-6G antibody in fractured mice
and observed impaired bone healing after 21 d, with diminished bone content as well as
impaired mechanical properties, implicating the important role of neutrophils in the very
early phase of fracture healing [44]. With regard to PMNCs in our model, we could not deter-
mine any impact of hypoxia on the frequency of granulocytes (Figs 2–4). Neutrophils are pri-
marily responsible for the removal of debris and spoilt cells in accordance with attracting
monocytes to the fracture site [48] in the very early inflammatory phase, while their impor-
tance seems to be diminished in the ongoing process of fracture healing. In our study here, we
could show the presence and survival of granulocytes within the first hours as well as their
time-dependent decline of their frequencies within the in vitro FH models, which may resem-
ble the in vivo situation (Figs 2–4). Although the frequency of granulocytes is time-depen-
dently diminished, we cannot exclude, that granulocytes in apoptosis or netosis or
degranulation processes have an influence on the ongoing process of fracture healing.
Among the adaptive immune cell populations, we observed a significantly enhanced hyp-
oxia-mediated reduction in the frequencies of CD4+ and CD8+ cells after incubation of FH
models for 72 h (Figs 2–4). In the line of our observation, reduction of an adaptive immune
response has been reported to accelerate during bone healing [49, 50]. In more detail, Toben
et al. demonstrated an accelerated fracture healing in recombination activating gene 1 knock-
out (RAG1(-/-)) mice lacking the adaptive immune system [49]. Although it has been
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demonstrated that proliferation of CD8+ cells is diminished under hypoxic conditions [51],
depletion of CD8+ T-cells in a mouse osteotomy model further has been reported to enhance
fracture healing [50]. These findings and our findings presented here indicate that the continu-
ous depletion of CD8+ T cells within the fracture site seems to be a feature beneficial for the
fracture healing process. However, in an ex vivo human FH model, we demonstrated a
decrease in lymphocyte survival after 24 h–independently of oxygen availability–although the
frequencies of lymphocytes after hypoxic incubation increase. The latter can be explained by
the relatively decreased granulocyte proportions after 24 h of incubation under hypoxia. Inter-
estingly, we could detect a relevant expression of active caspases indicating apoptosis in granu-
locytes only after 24 h of incubation under hypoxia. However, human lymphocytes from ex
vivo human FH models did express active caspases under all incubation conditions but with
the highest expression after 24 h under hypoxia which is in the line with the findings in the
equine FH model after 48 h [47].
Moreover, it has been well demonstrated that MSCs exhibit immunosuppressive functions
[52], and that they are immunotolerant [53] and known to inhibit the proliferation of T-lym-
phocytes [42, 52, 54–56]. Here, we demonstrate that the increase in the frequency of MSCs
over time is associated with a decrease of T-lymphocytes when investigating the incubation of
these cells under hypoxia. This anti-correlative development may indicate that MSCs are limit-
ing the initial inflammatory hypoxic phase of fracture healing in a human ex vivo FH model
and also in an equine in vitro FH model.
In view of the impact of hypoxia on the expression of selected genes in our equine in vitro
FH model, we observed that upregulation of osteogenic (RUNX2, SPP1), hypoxia-induced
(PGK1, LDHA, PFKFB3, SLC2A1) and angiogenic (VEGFA, MIF) genes/factors essential for
fracture healing after incubation for 48 h takes place at a higher extent under hypoxic than
under normoxic conditions (Fig 5). In this line of observation, we could previously demon-
strate a time-dependent increase in the expression of the osteogenic RUNX2 and SPP1 in a
human ex vivo FHs [18]. Although we demonstrate an increase in the expression of PPARG (a
key marker for the adipogenic differentiation of MSCs under normoxia), its upregulation is
abolished under hypoxia. Thus, hypoxia seems to shift MSCs into the osteogenic lineage, as
demonstrated previously [43].
To analyze the impact of MSCs, we compared the in vitro generated FH models (blood
coagulates with MSCs) with blood coagulates without MSCs, focusing on the expression of
selected genes (Fig 6). In general, MSCs contribute either directly or indirectly to the induction
of gene expression from osteogenic (RUNX2, SPP1), hypoxia-induced (PGK1, LDHA,
PFKFB3, SLC2A1) and angiogenic (VEGFA, MIF) factors essential for fracture healing. The
contribution of MSCs in the equine in vitro FH models demonstrate a similar pattern of
expression with regard to the hypoxia-induced genes LDHA, PGK1 and SLC2A1 after 48 h
when compared to in human ex vivo as well as in vitro studies [18, 47]. The induction of these
genes especially under hypoxia may reflect the adaptation towards a hypoxic environment and
the shift towards anaerobic glycolysis [57–60]. All hypoxia-related genes were to a great extent
more highly expressed in the in vitro hematomas when compared to blood coagulates, indicat-
ing the huge influence of MSCs on the expression of hypoxia-induced genes/factors in the FH
models, which also involves the gene expression of VEGFA and MIF coding for angiogenic fac-
tors. VEGFA is known to be expressed locally by pre-osteoblasts [61] and MSCs, and also plays
an important role in the fate of MSCs towards either adipocyte or osteoblast lineage [61, 62].
Several studies identified VEGFA as a key factor in osteogenesis as well as in angiogenesis [63–
65]. Upregulation of VEGFA in our model may indicate the initiation of fracture healing-rele-
vant processes involving angiogenesis and vascularization. MIF is also an essential molecule
for fracture healing [25, 66] and several knock-out rat models have underlined the importance
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of MIF, demonstrating a delayed fracture healing in the absence of MIF [67, 68]. MIF is
secreted by MSCs [69] and is known to promote their survival [70].
Taken together, we observed in our present equine in vitro FH model profound similarities
to our previously published results derived from a human in vitro FH model. These concern
the expression of genes analyzed for the upregulation of angiogenic and hypoxia-induced
markers, and the indication that they are more pronounced under hypoxic conditions [47].
Conclusion
In our study presented here, we characterized equine immune cells as well as MSCs and used
these cells to establish an equine in vitro FH model. We demonstrate that hypoxia favors the
survival of MSCs over that of immune cells and that the expression of fracture healing-relevant
genes, most often enhanced by hypoxia, is widely induced. Compared to human in vitro and
ex vivo data and in vivo data based on animal models, we could highlight significant similari-
ties. However, further investigations of ex vivo equine fracture hematoma are needed to vali-
date our approach and to clarify the cellular and molecular process of the initial phase of
fracture healing in the “patient” horse more in detail.
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